Summary
Non-enzymatic glycosylation of proteins is thought to play an important role in the development of diabetic vascular disease. Advanced glycosylation end products have been shown to accumulate on basement membranes and collagen in diabetes, and receptors for such adducts have recently been found on murine macrophages. We have observed that human monocytes activated by endotoxin express receptors for advanced glycosylation end products of similar affinity and number as has been previously reported for murine macrophages. In addition, there is an increased adherence of activated human monocytes to a nonenzymatically glycosylated albumin substrate, and such adhesion can be competitively inhibited up to 50% by soluble, non-enzymatically glycosylated albumin. We suggest that increased adherence of activated monocytes to non-enzymatically glycosylated proteins in the vessel wall may result in monocyte stimulation and/or local monocyte accumulation and thereby contribute to vascular disease in diabetes.
Article PDF
Similar content being viewed by others
References
Cerami A, Vlassara H, Brownlee M (1985) Protein glycosylation and the pathogenesis of atherosclerosis. Metab Clin Exp 12 [Suppl 1]: 37–42
Winterhalter KH (1985) Nonenzymatic glycosylation of proteins. Prog Clin Biol Res 195: 109–129
Vlassara H, Brownlee M, Cerami A (1986) Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem 32 [Suppl 10]: B37–41
Brownlee M, Cerami A, Vlassara H (1988) Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 4: 437–451
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315–1321
Reynolds TM (1965) Chemistry of nonenzymatic browning. Adv Food Res 14: 167–283
Monnier VM, Cerami A (1981) Nonenzymatic browning in vivo: possible process for aging for long-lived proteins. Science 211: 491–493
Monnier VM, Cerami A (1982) Nonenzymatic glycosylation and browning of proteins in diabetes. Clin Endocrinol Metab 11: 431–452
Sakurai T, Takahashi H, Tsuchiya S (1984) New fluorescence of nonenzymatically glycosylated human serum albumin. FEBS Lett 176: 27–31
Vlassara H, Brownlee M, Cerami A (1985) High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82: 5588–5592
Vlassara H, Brownlee M, Cerami A (1986) Novel macrophage receptor for glucose-modified proteins is distinct from previously-described scavenger receptors. J Exp Med 164: 1301–1309
Radoff S, Vlassara H, Cerami A (1988) Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. Arch Biochem Biophys 263: 418–423
Vlassara H, Brownlee M, Cerami A (1988) Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37: 456–461
Dorn AR, Moriarty CS, Osborne JP, Schultz LC, McCarthy GP, Lister KA, Horne LA (1986) A new system for mononuclear cell separation. Am Clin Prod Rev 5: 26–33
Fraker PJ, Speck JC (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Comm 80: 849–857
Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, Cerami A (1987) Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages. A model for turnover of aging cells. J Exp Med 166: 539–549
Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240: 1546–1548
Molvig J, Baek L, Christensen P, Manogue KR, Vlassara H, Platz P, Nielsen LS, Svejgaard A, Nerup J (1988) Endotoxinstimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences. Scand J Immuno 27: 705–716
Chollet-Martin S, Ollivier V, Amiral J, De-Prost D (1988) Binding of an anti-D dimer monoclonal antibody to endotoxin-activated monocytes. Demonstration by immunogold-silver staining. Thrombos Res 52: 1–9
Henry MM, Moore JN (1988) Endotoxin-induced procoagulant activity in equine peripheral blood monocytes. Circ Shock 26: 297–309
Lasser A (1983) The mononuclear phagocytic system: a review. Hum Pathol 14: 108–126
Lee SHS, Epstein LB (1980) Reversible inhibition by interferon of the maturation of human peripheral blood monocytes to macrophages. Cell Immunol 50: 177–190
Nicholls K, Mandel TE (1989) Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. Lab Invest 60: 486–491
Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629–1632
Schwarz CJ, Sprague EA, Kelley JL, Valente AJ, Suenram CA (1985) Aortic intimal monocyte recruitment in the normo and hypercholesterolemic baboon. Virch Arch A 405: 175–191
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilcrease, M.Z., Hoover, R.L. Activated human monocytes exhibit receptor-mediated adhesion to a non-enzymatically glycosylated protein substrate. Diabetologia 33, 329–333 (1990). https://doi.org/10.1007/BF00404635
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00404635